Intestinal microbiota in liver diseases: current state of the problem
Journal Title: Сучасна гастроентерологія - Year 2019, Vol 0, Issue 3
Abstract
The article presents analysis of the recent literature data, the results of experimental and clinical studies on role of participation the intestinal microbiota in the pathogenesis of various liver diseases: viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, primary sclerosing cholangitis, liver cirrhosis and hepatocellular carcinoma. Particular attention is paid to increasing intestinal permeability, which creates conditions for bacterial translocation, activation of the systemic inflammatory response, increased hyperdynamic blood flow and deterioration of the functional state of the liver. As a striking example of the effect of intestinal microbiota on the state of the liver, data on small intestinal bacterial overgrowth syndrome (SIBR) are presented. There was a high incidence of SIBR in chronic liver diseases, a relationship between increased intestinal permeability and severity of impaired liver function, development and severity of hepatic encephalopathy, and the likelihood of spontaneous bacterial peritonitis. Role of intestinal microbiota in the development of bacterial complications in liver cirrhosis, especially spontaneous bacterial peritonitis, is discussed. It is shown that intestinal dysbiosis is involved in dysregulation of the cell death/regeneration balance that underlies carcinogenesis. It is concluded that it is reasonable to include drugs correcting the composition of intestinal microbiota in therapy of a number of liver diseases. The advantages of rifaximin administration have been outlined in the improvement of liver functional state at non-alcoholic steatohepatitis, hepatic encephalopathy by means of correcting the composition of the intestinal microbiome.
Authors and Affiliations
N. B. Gubergrits, N. V. Byelyayeva, E. V. Berezhna, A. Ye. Klochkov, P. G. Fomenko, A. V. Tsys
Keywords
Related Articles
- EP ID EP616019
- DOI 10.30978/MG-2019-3-79
- Views 142
- Downloads 0
A place of plasma substitutes in the treatment of patients with chronic viral hepatitis
Objective — to assess the efficacy of plasma substitute (Reosorbilact) in patients with chronic viral hepatitis. Materials and methods. The investigation involved 60 patients with chronic viral hepatitis (CVH), who were...
State of the hepatobiliary system in boys with hypoandrogenism
Objective — to study the state of hepatobiliary system in boys/youths with delayed puberty. Materials and methods. The study involved 37 boys and youths with hypoandrogenism, aged 13 — 18 years, who were examined in the...
United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis
-
New directions in the treatment of irritable bowel syndrome: focus on microbiosis
Fecal transplantation (FT) is the process of transplanting purified fecal material from a healthy donor to a recipient. The available evidence confirmed the positive role of FT in the treatment of a number of diseases, i...
The relationship of serum inflammatory markers with metabolic disorders at the non-alcoholic fatty liver disease
Objective — to study the serum levels of proinflammatory markers and determine their role in the formation of metabolic disorders in patients with non-alcoholic fatty liver disease (NAFLD). Materials and methods. Examin...